Insys Leverages Synthetic CBDs to Target Numerous Markets

Insys Therapeutics Inc. (INSY), a commercial-stage specialty pharmaceutical company developing supportive care products, recently received orphan drug status for its pharmaceutical cannabidiol (“CBD”) for the treatment of Glioblastoma Multiforme (“GBM”). GBM is the most common and aggressive form of malignant primary brain tumor affecting thousands of patients worldwide. Unlike many other CBD-focused companies in the space, the company…

The post Insys Leverages Synthetic CBDs to Target Numerous Markets appeared first on Marijuana Index.